Roman Fleck

Roman currently serves as the CEO of Janpix, an oncology-focused start-up. He was formerly an advisor to Index Ventures and, before that, a Principal at Index, where among others he invested in and represented the firm on the boards of GlycoVaxyn (sold to GlaxoSmithKline), Versartis (Nasdaq: VSAR), and Novocure (Nasdaq: NVCR). He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he was leading development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage.

Roman received a PhD from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as issued patents.